BAYER PHARMA AKTIENGESELLSCHAFT;THE BROAD INSTITUTE, INC.;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
TIMOTHY A. LEWIS,ALEX BURGIN,MONICA SCHENONE,XIAOYUN WU,HEIDI GREULICH,MATTHEW MEYERSON,LUC DE WAAL,ANTJE MARGRET WENGNER,KNUT EIS,PHILLIP LIENAU,ULRIKE SACK,MARTIN LANGE
申请号：
US16075077
公开号：
US20190365770A1
申请日:
2017.02.03
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
